Cancer clot care: do longer blood thinners help or harm?
NCT ID NCT07388056
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study reviewed medical records of 169 cancer patients who had blood clots and took blood thinners for at least six months. Researchers compared extended use of lower-dose blood thinners versus standard doses to see which better prevents new clots and reduces bleeding. The goal is to find the safest, most effective long-term treatment for cancer-associated thrombosis.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Anticoagulants (blood thinners such as warfarin, low molecular weight heparin, and DOACs)
- What this could lead to
- If successful, this could help doctors decide the best duration and dose of blood thinners for cancer patients with blood clots, potentially reducing clot recurrence and bleeding risks.
- What could go wrong
- This is a retrospective observational study, not a controlled trial, so results may show associations but not prove cause and effect. The small sample size and single-center design limit how widely the findings can be applied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER-ASSOCIATED THROMBOSIS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.